Latest VectorY Therapeutics News & Updates

See the latest news and media coverage for VectorY. We track all announcements, press releases, and industry mentions in real time, all in one place.

VectorY Therapeutics (VectorY)

Biotechnology company developing vectorized antibody therapies for neurodegenerative diseases

vectorytx.com

Headquarters: Amsterdam, Netherlands
Founded year: 2020
Company type: Private company
Number of employees: 110–200
Industry: Pharmaceuticals

Last updated September 29

Latest news about VectorY Therapeutics (VectorY)

In short: VectorY tripled its PIONEER-ALS trial to 36 participants before efficacy data.

Company announcements

September 29 VectorY

VectorY expands PIONEER-ALS clinical trial size

The company increased the Phase 1/2 study from 12 to 36 participants for its vectorized antibody VTx-002 targeting TDP-43 pathology in ALS.

December 3, 2025 VectorY

VectorY Therapeutics receives FDA IND clearance for VTx-002 ALS trial

The PIONEER-ALS Phase 1/2 trial evaluates safety and efficacy of VTx-002, a vectorized antibody targeting TDP-43 pathology in ALS patients.

December 16, 2024 VectorY

VectorY appoints Jim Scibetta as new CEO

Former CEO Sander van Deventer becomes President of R&D. Lead program VTx-002 advances to IND-enabling studies after FDA feedback. Company expands to Boston.

November 13, 2023 VectorY

VectorY raises €129 million Series A financing

The round, co-led by EQT Life Sciences and Forbion, funds clinical development of VTx-002 for ALS and preclinical pipeline programs. New board members join.

Media coverage

April 28 Yahoo Finance

VectorY Therapeutics Receives U.K. MHRA Authorization and EMA Approval to Initiate Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People Living with Amyotrophic Lateral ...

VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, today announced the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) and, the European...

February 9 Yahoo Finance

VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS)

VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the first participant has been dosed in its Phase 1/2 PIONEER-ALS...

February 5 ALS News Today

First ALS patient dosed in study of experimental gene therapy VTx-002

The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.

December 2, 2025 The Eagle-Tribune

VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology ...

VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company...

Never miss news about VectorY

Track VectorY and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

VectorY competitors & trending companies

Browse news for competitors to VectorY and other trending companies.